Business
Monopar Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates
WILMETTE, Ill., May 14, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical‐stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced first quarter 2026 financial results and provided business updates. Recent Program Developments ALXN1840 for Wilson Disease – NDA Submission on Track for Mid-2026 In April 2026, Monopar presented new analyses from the randomized controlled Phase 3 F
About this update from Monopar Therapeutics Inc.
[{"type":"image","alt":"Monopar Therapeutics Inc.","displaySize":"","headline":null,"caption":"Monopar Therapeutics Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":56,"url":"https://media.zenfs.com/en/globenewswire.com/78ad59c9c1072dda3cd2bbfc9abc4430"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/8kyzQtbKIBMgzTjovzij7w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTc4/https://media.zenfs.com/en/globenewswire.com/78ad59c9c1072dda3cd2bbfc9abc4430","width":300,"height":56},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/8kyzQtbKIBMgzTjovzij7w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTc4/https://media.zenfs.com/en/globenewswire.com/78ad59c9c1072dda3cd2bbfc9abc4430","width":300,"height":56}},"lazy":false},{"type":"text","content":"WILMETTE, Ill., May 14, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical‐stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced first quarter 2026 financial results and provided business updates.","length":323,"tagName":"p"},{"type":"text","content":"Recent Program Developments","length":27,"tagName":"p"},{"type":"text","content":"ALXN1840 for Wilson Disease – NDA Submission on Track for Mid-2026","length":66,"tagName":"p"},{"type":"text","content":"In April 2026, Monopar presented new analyses from the randomized controlled Phase 3 FoCus trial of ALXN1840 (tiomolibdate choline, TMC) at the American Academy of Neurology (AAN) Annual Meeting 2026. The late-breaker oral and poster presentation, titled “Greater clinical benefit with tiomolibdate choline versus standard-of-care in neurologic Wilson disease patients in the Phase 3 FoCus Trial,” demonstrated greater neurologic benefit of ALXN1840 versus standard of care (“SoC”) in Wilson disease patients with neurologic symptoms at baseline.","length":546,"tagName":"p"},{"type":"text","content":"These results from the FoCus trial will also be presented in a poster at the 12th Congress of the European Academy of Neurology (EAN) in Geneva, Switzerland, June 27-30, 2026. Dr. Aurélia Poujois, MD, PhD, of the Adolphe de Rothschild Foundation Hospital, a leading authority in Wilson disease, will present on June 28 at 12:50 CEST.","length":333,"tagName":"p"},{"type":"text","content":"Monopar will also present at the European Associa...